$DOCS

Wampler Kira Scherer sold $58K of DOCS

Wampler Kira Scherer sold 2,000 shares of Doximity, Inc. (DOCS) at $28.91 on 2026-10-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Wampler Kira Scherer
Published Oct 5, 2026, 8:08 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 5, 2026, 8:13 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$DOCS
Neutral
high confidence
Mentioned
$DOCS
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$DOCSNeutralLow
01

Why it matters

The disclosed sale is modest and pre‑arranged, suggesting low immediate market impact.

02

Market read

A routine insider sale with limited price effect; primarily of interest to short‑term traders monitoring insider activity.

03

What to watch

Potential upcoming dilution or secondary offering not disclosed.

Relevance 2/10Novelty 2/10Timing: after‑hours filing on Oct 5

Background

Form 4 filings disclose insider transactions and are used by investors to gauge insider sentiment.

Company-level read

Ticker impact

$DOCSNeutralHigh confidence
Context

Director Wampler Kira Scherer sold 2,000 DOCS shares for $57,820 under a 10b5‑1 plan, reducing her holding to 27,923 shares.

Expected impact

likely slight downward pressure as the market prices the insider sell.

Evidence & confidence

Small size relative to market cap and pre‑arranged plan suggest limited impact.

Market effects

Minimal effect on the broader health‑tech sector.

No discernible regional impact.

Limited to investors tracking insider activity.

Counterpoint

The sale could be unrelated to company fundamentals and merely portfolio rebalancing.

Key entities

  • Doximity, Inc.

    Provider of digital tools for physicians, ticker DOCS.

  • Wampler Kira Scherer

    Director of Doximity who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

MedAI 8/10

Doximity’s ex-chief revenue officer to pay nearly $500K to SEC: Trial Balance

Doximity's former chief revenue officer, Paul Jorgensen, was ordered to pay $490,000 to the SEC for insider trading. He sold shares based on nonpublic information ahead of negative earnings announcements, avoiding losses and making $2.2 million in profits. Jorgensen was also sentenced to 26 months in prison and ordered to forfeit $2.5 million in a parallel criminal case.

$DOCSMed

Doximity stock falls as Freedom Capital cuts to hold

Doximity Inc (DOCS) shares dropped 5.6% after Freedom Capital downgraded it to Hold, raising its price target to $27. The company beat Q1 estimates, increased full-year revenue guidance, but lowered EBITDA outlook due to AI investment. Freedom Capital noted strong AI search traction but margin concerns and core business softening.

$DOCSMedAI 8/10

Doximity (DOCS) Q1 2027 Earnings Call Transcript

Doximity (DOCS) reported Q1 2027 revenue of $156.6 million, up 7% year over year, and adjusted EBITDA of $74.8 million. The company raised full-year 2027 revenue guidance to $671 million to $681 million. It said AI workflow and scribe usage grew, repurchased $91.6 million of stock, and ended June 30 with $688 million in cash and marketable securities.

$DOCSMedAI 8/10

Doximity (DOCS) Q1 2027 Earnings Call Transcript

Doximity (DOCS) reported Q1 FY2027 revenue of $156.6 million, up 7% year over year, with adjusted EBITDA of $74.8 million. The company raised full-year 2027 revenue guidance to $671 million to $681 million and adjusted EBITDA guidance to $309 million to $329 million. It also repurchased $91.6 million of stock and ended June 30 with $688 million cash and marketable securities.